GlassScriptPhysician profile
Carla A Gustovich
NPI 1003981044
$11,010.59
in general payments reported to CMS, 2019-2025
37 companies · $2,227 in 2025
The $2,227 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $977 · 2021: $1,245 · 2022: $1,248 · 2023: $2,094 · 2024: $2,178 · 2025: $2,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,319 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,319.31 |
| Education | $179.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,105.18 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $949.86 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $948.37 | 2020-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $946.34 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $841.98 | 2019-2025 | Jublia, Arazlo, Siliq |
| Genzyme Corporation | $660.71 | 2019-2025 | |
| Amgen INC. | $576.61 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $558.36 | 2019-2025 | |
| Allergan, INC. | $512.36 | 2020-2022 | |
| Galderma Laboratories, L.P. | $457.45 | 2019-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $370.97 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $247.21 | 2023-2025 | Zoryve |
| Ucb, INC. | $246.81 | 2020-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $226.71 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $167.38 | 2023-2024 | Adbry |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $153.82 | 2024 | Vtama |
| Almirall LLC | $134.82 | 2019-2023 | Klisyri |
| Pfizer INC. | $131.83 | 2022-2025 | |
| Dermira, INC. | $118.81 | 2019-2021 | |
| Encore Dermatology INC. | $77.56 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $69.07 | 2019 | |
| Vyne Pharmaceuticals INC. | $63.76 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $60.80 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $59.31 | 2019-2020 | |
| Journey Medical Corporation | $40.79 | 2023-2025 | |
| Celgene Corporation | $39.89 | 2019 | |
| Botanix Sb INC | $34.23 | 2025 | Sofdra |
| Nabriva Therapeutics, Plc | $28.75 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.95 | 2023 | Spevigo |
| Organon LLC | $24.92 | 2025 | Vtama |
| Epi Health, LLC | $24.09 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $19.29 | 2019 | |
| Kyowa Kirin, INC. | $19.02 | 2022 | |
| Fidia Pharma USA INC. | $18.08 | 2025 | |
| Genentech USA, INC. | $17.42 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.15 | 2021 | |
| Cipher Pharmaceuticals US LLC | $15.93 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Gustovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.